Prostate Cancer

The designation was approved based on interim data from a phase 1 study that assessed SV-102 among males with metastatic castrate-resistant prostate cancer (mCRPC).

Precision oncology represents an evolution in therapeutic practice.

These combination therapies have demonstrated longer PFS with a tolerable AE profile.

The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.

With precision medicine, patients undergoing treatment are living longer without disease recurrence or progression and with fewer adverse effects, resulting in preservation of quality of life.

According to investigators, additional research is necessary to further understand how lutetium impacts overall survival in patients with metastatic prostate cancer.

Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.

AACR has urged Congress to provide billions more in funding for cancer research, prevention efforts, and expedited review of cancer-related medical products.

Precision medicine in pharmacy has the potential to revolutionize patient care by optimizing drug selection, dosing, and monitoring.

Patients with cancer and survivors of cancer that had engaged in administrative tasks to effectively estimate costs or pay for care was associated with an 18% increase in cost-related treatment delays or treatment nonadherence.

Investigators found that artificial intelligence chatbots did not consistently provide recommendations for cancer treatment that correspond with NCCN guidelines.

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis.

Niraparib and abiraterone acetate (Akeega; Janssen Pharmaceutical Companies of Johnson & Johnson) is the first-and-only dual action tablet that combines a PARP inhibitor with abiraterone acetate administered with prednisone.

Risks of genitourinary and gastrointestinal toxicity were reduced significantly, but longer follow-up is necessary to examine potential future issues.

Clinical trial results showed that the combination significantly improved radiographic progression-free survival compared with enzalutamide monotherapy for homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

The ASCO abstracts were on the TALAPRO-2 trial (abstract 5053) and PROpel trial (abstract 5012).

Investigators previously reported a statistically significant improvement in radiographic progression-free survival in the full intention-to-treat population of adults with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

The radiohybrid imaging agent allowed positron emission tomography to identify prostate cancer with an 83% detection rate.

Immature data suggest enzalutamide combination improves overall survival in patients with high-risk biochemical recurrence.

Relative risk of cancer-related death differed according to age of diagnosis.

Despite the potential for clinical benefit, triplet therapies have added complexities, monitoring needs, toxicities, and costs associated with additional pharmacologic therapy.

The treatment shows positive results in metastasis-free survival for men with non-metastatic hormone-sensitive prostate cancer, Pfizer and Astellas announce.

There is no single thing that can prevent all cancer risk, but there are 6 pillars of lifestyle that people can adopt to best prevent the disease.

Niraparib with abiraterone acetate could be the first dual-action tablet for patients with metastatic castration-resistant prostate cancer and BRCA mutations.

The kit is now approved in the US to select patients with metastatic prostate cancer who are candidates for the only FDA-approved PSMA-directed radioligand therapy.

The KEYNOTE-641 and -789 trials did not demonstrate improvements or meet the primary endpoints in metastatic castration-resistant prostate cancer and metastatic nonsquamous non–small cell lung cancer.

Positive data on the novel prostate cancer combination treatment was presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Olaparib with abiraterone increased survival in patients with metastatic prostate cancer compared to the current standard of care, according to a session at the ASCO Genitourinary Cancers Symposium.

The FDA approved darolutamide in 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer based improved metastasis-free survival.

New data identifying a particular gene expression signature will be presented at the 2023 ASCO Genitourinary Symposium.